Browsing Tag
VEPPANU
2 posts
Why ESR1 mutation targeting is critical in metastatic breast cancer treatment
FDA approves VEPPANU. Discover why ESR1 mutation targeting is reshaping metastatic breast cancer treatment and what it means next.
Arvinas wins first FDA-approved PROTAC as ARVN stock tests investor patience
PROTAC drugs finally have FDA validation. Arvinas now faces the harder question: can VEPPANU become a commercial oncology asset?